体育投注正规网址. Once the DUA is completed Pfizer will upload the de-identified data into the Vivli platform for use by researchers. Access to data needed for research is provided on a password-protected platform via . This platform allows researchers to conduct research on the site and to download their analyses. Access is provided for 12 months. Extensions are possible when justified and upon review and approval. Commonly used statistical software is provided on the platform so researchers can conduct their analyses. More information about the available software is on .

Researchers are invited to conduct their research in a private workspace. This workspace is not accessed by Pfizer or any other third party unless researchers provide permission. To protect research participants privacy & confidentiality and ensure the data is used for the agreed research purpose, controls are in place to prevent the download of de-identified data provided for access.

In cases where a request is rejected based on scientific merit, the request, along with the record of our denial of the request, shall be forwarded to an Independent Review Panel for a final decision. The Independent Review Panel is composed of scientists and/or health care professionals who are not Pfizer employees. The outcome of the Independent Review Panel decision will be shared with the applicant. The Independent Review Panel’s decision is considered final and binding.

Researchers are responsible for gaining any other approvals that are required for the research (for example, from ethics committees, institutional review boards, relevant research institutions or funding bodies).

After the researcher has completed the research per the approved study proposal and analysis plan, the researcher is expected to publicly share the results per the executed DUA.